Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs

doi:10.3748/wjg.v12.i31.5078

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 31

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3028)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

338

HTML

2452

Tables (1-1)

238

Sum=3028

Aug 21, 2006 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastroenterol. Aug 21, 2006; 12(31): 5078-5080
Published online Aug 21, 2006. doi: 10.3748/wjg.v12.i31.5078

Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy: Is there still a role for these drugs

Carmen Verge, M Isabel Lucena, Enrique López-Torres, M José Puche-García, Enrique Fraga, Manuel Romero-Gomez, Raúl J Andrade

Carmen Verge, M Isabel Lucena, Enrique López-Torres, M José Puche-García, Clinical Pharmacology Service, Virgen de la Victoria University Hospital, School of Medicine, Málaga, Spain

Enrique Fraga, Gastroenterology Service, University Hospital Reina Sofia, Córdoba, Spain

Manuel Romero-Gomez, Gastroenterology Service, University Hospital Virgen de Valme, Sevilla, Spain

Raúl J Andrade, Liver Unit, Department of Gastroenterology, University Hospital, Málaga, Spain

Author contributions: All authors contributed equally to the work.

Supported by a research grant from the Agencia Española del Medicamento and a FIS grant, No.041688

Correspondence to: M Isabel Lucena, Department of Clinical Pharmacology, Facultad de Medicina, E-29071-Málaga, Spain. lucena@uma.es

Telephone: +34-952-131572

Received: March 6, 2006
Revised: March 20, 2006
Accepted: March 27, 2006
Published online: August 21, 2006

Abstract

Disulfiram and calcium carbimide are two alcohol deterrants widely used in alcoholism treatment, however, there exist great concerns over their safety. Reports on hepatotoxicity, mainly related to disulfiram therapy, have been published. The hepatotoxic potential of calcium carbimide is less well characterized. Here, we describe four cases of liver damage related to this therapeutic group that were submitted to a Registry of hepatotoxicity and point out the limitations that we face when prescribing these compounds. A reassessment of the role of these compounds in the management of alcohol dependence is clearly needed.

Keywords: Calcium carbimide; Disulfiram; Hepatotoxicity